F10 and atrial fibrillation: The PIONEER AF-PCI trial, an open-label, randomised, multicentre trial compared triple therapy consisting of VKA, P2Y12 inhibitor (mainly clopidogrel) and ASA to the factor Xa-antagonist rivaroxaban (with a lower dose than approved for SPAF of 1 × 15mg/day instead of 1 × 20mg/day for duration of combination therapy, or 1 × 10mg/day if creatinine clearance was impaired at 30–50 ml/min) in combination with a P2Y12 inhibitor or rivaroxaban in a low dose of 2 × 2.5mg/day in combination with ASA and a P2Y12 inhibitor in 2124 patients.